A phase II trial in HER2-positive early breast cancer found that a pyrotinib-based neoadjuvant regimen delivered pathological response rates comparable to the standard trastuzumab–pertuzumab combination. The results add an additional oral/targeted option to the evolving neoadjuvant HER2 landscape. The trial’s comparative framing matters operationally for oncology programs because it targets a common decision point—whether to swap established anti-HER2 backbone therapy for a different mechanism or administration model. Further follow-up on long-term endpoints will be key for determining where the regimen fits in routine practice. For sponsors and clinicians, the study highlights continued momentum around pyrotinib-based strategies and the need to map response biomarkers, resistance patterns, and safety to optimize patient selection.